NCT00600275View on ClinicalTrials.gov

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2010

Conditions
Solid TumorsBreast CancerCowden Syndrome
Interventions
DRUG

BGT226

Trial Locations (6)

78229

Cancer Therapy and Research Center (CTRC), San Antonio

89135

Nevada Cancer Center, Las Vegas

02114

Massachusetts General Hospital, Boston

02115

Dana Faber Cancer Institute, Boston

Unknown

Princess Margaret Hospital, Toronto

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY